- Home
- HYFM vs CRIS Comparison
HYFM vs CRIS Comparison
Compare HYFM & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYFM | CRIS |
|---|---|---|
| Founded | 1977 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2M | 12.9M |
| IPO Year | 2020 | 2000 |
Fundamental Metrics
Financial Performance| Metric | HYFM | CRIS |
|---|---|---|
| Price | $1.51 | $0.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 47.6K | ★ 1.2M |
| Earning Date | 03-04-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $146,443,000.00 | $11,650,000.00 |
| Revenue This Year | N/A | $6.13 |
| Revenue Next Year | $51.57 | $7.86 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 13.56 |
| 52 Week Low | $1.45 | $0.77 |
| 52 Week High | $6.89 | $3.57 |
Technical Indicators
Market Signals| Indicator | HYFM | CRIS |
|---|---|---|
| Relative Strength Index (RSI) | 38.04 | 41.62 |
| Support Level | $1.61 | $0.87 |
| Resistance Level | $1.81 | $0.96 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 8.05 | 43.59 |
Price Performance
Historical ComparisonAbout HYFM Hydrofarm Holdings Group Inc.
Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.